Drug Discovery can now be Accelerated with AxoSim's New...
pharmatechoutlook

Drug Discovery can now be Accelerated with AxoSim's New 'Mini-Brain' Platform!

By Pharma Tech Outlook | Tuesday, June 18, 2019

Lowry Curley, Ph.D., CEO, AxoSim

Mini-Brain technology enables scientists to study the functions of the brain, identify toxic substances, and test new therapies in humans rather than animal models at an early stage of research.

FREMONT, CA: What is the justification for an astounding degree of sensory drug failures? Why are neurological drug trials unsuccessful despite intricate animal examinations? To answer such questions, AxoSim, a neuroscience discovery platform provider licensed exclusive Mini-Brain technology from Johns Hopkins University. The intellectual property rights of revolutionary Mini-Brain technology include the use of induced pluripotent stem cells (iPSCs) to mimic sophisticated functionalities of the human brain. 

“Acquiring rights to the intellectual property underlying the Mini-Brain technology is a major step forward in our drive to transform neurology drug research,” said Lowry Curley, Ph.D., Chief Executive Officer of AxoSim. “Mini-Brains are live organoids that mimic multiple brain functions, allowing for a wide variety of applications in neurotoxicity and neurological diseases with the potential to substantially speed-up and increase the effectiveness of new drug R&D. The Mini-Brain technology complements our innovative Nerve-on-a-Chip platform and accelerates our strategy of providing the broadest and most scientifically robust neuroscience models to our growing roster of biopharmaceutical partners.”

Thomas Hartung, MD, Ph.D., Johns Hopkins University

AxoSim’s Mini-Brain platform develops tiny, self-organized brain-like organoids for neuroscience research using adult pluripotent stem cells that have been genetically reprogrammed to return to the embryonic stem-cell state.

Mini-Brain technology has the potential to reform drug development related to Alzheimer’s, Parkinson’s, multiple sclerosis, and other neurodegenerative diseases. This technology enables scientists and researchers to examine multiple brain functions, screen for toxic materials, and analyze new therapies in humans rather than animal models. Every micro-anomalies resulted due to the inclusion of animal models gets washed away with the introduction of Mini-Brain. In addition to a perfect replacement, Mini-Brain technology performs without compromising the health of a subject.

An Addition to the Team

With regard to this licensing, Dr. Thomas Hartung, Doerenkamp-Zbinden Chair for Evidence-based Toxicology and Director of the Center for Alternatives to Animal Testing at the Johns Hopkins Bloomberg School of Public Health, will serve as the Consulting Vice President of Scientific Affairs for AxoSim.

“We are thrilled that Dr. Thomas Hartung has chosen to serve as a scientific consultant to AxoSim. Dr. Hartung’s experience in applying advanced tissue engineering, stem cell, and high content data technologies to empower early-stage neuroscience and toxicology research will be very valuable as we continue to refine the Mini-Brain technology,” mentioned Curley. 

Weekly Brief

New Editions